We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Breath or Urine Analysis May Indicate Disease

By LabMedica International staff writers
Posted on 18 Mar 2009
A sensor is being developed that will be able to analyze a patient's breath or urine to determine whether the patient has breast cancer, lung cancer, diabetes, or asthma. More...


The sensor device, known as the optofluidic ring resonator (OFRR), is an optical gas sensor that consists of a polymer-lined glass tube that guides the flow of a gas vapor, and a ring resonator that detects the molecules that pass through the glass tube. As the gas vapor enters the device, molecules in the vapor separate and react to the polymer lining. Light makes thousands of loops around the gas or liquid sample. The more the light loops around the sample, the more the light energy interacts with the gas vapor. These repetitive interactions enable the detection of a very small number of vapor molecules.

The device is being developed by Professor Xudong "Sherman" Fan, a University of Missouri (Columbia, MO, USA) scientist. It will analyze breath or urine samples for volatile markers inside the body that indicate disease. The markers, such as alkanes, acetones, or nitric oxide, give doctors information about what is happening inside the body and can be used as a diagnostic tool.

"Little traces of certain gas molecules in the breath or urine tell us if anything unusual is going on in the body," said Professor Fan. "Measuring these volatile markers would be a noninvasive way to determine if a disease is present without having to draw blood or complete a biopsy. In addition to the biomarkers already discovered, many more potential volatile markers are still under investigation."

Optical gas sensors have broad applications in the fields of medical care, industry, military, environment, and homeland security. In addition to OFRR's application in the medical industry, the device also can improve the detection of explosives on the battlefield. Currently, the existing gas vapor sensor technology is very bulky with equipment weighing more than 100 pounds and is difficult to use in the field.

"We hope to design a vapor sensor that has ultra-high sensitivity, specific and rapid response to a certain molecule, as well as the ability of on-the-spot chemical analyses, which usually requires the sensor to be small, portable, reusable, and have less power consumption," said Professor Fan.

Related Links:

University of Missouri



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Molecular Diagnostics

view channel
Image: Signatera uses ctDNA analysis to identify residual tumor-derived genetic material after definitive treatment (image credit: Adobe Stock)

Blood-Based MRD Test Predicts Recurrence Risk After Lung Cancer Surgery

Assessing recurrence risk after surgery for early-stage non-small cell lung cancer remains challenging, complicating adjuvant therapy and surveillance decisions. Blood-based molecular residual disease... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.